MDPI announces the publication of the following issue:
Mar. Drugs, Volume 11, Issue 5 (May 2013), Pages 1427-1762
Although terrestrial myxobacteria have been extensively studied and are known to produce a range of secondary metabolites with a remarkable variety of unusual structures, their marine counterparts have only recently been discovered.
Gabriele M. König and co-workers, University of Bonn, Germany, have isolated a marine myxobacterium from a mud sample from the coast of the island Prerow, Germany. Analysis showed that the bacterium was Enhygromyxa salina, which is closely related to microorganisms previously termed “unculturable”. As this bacterium was found to have persistent antibiotic activity towards gram-positive microorganisms, it was chosen for detailed investigation.
Florida Atlantic University Harbor Branch Oceanographic Institute (HBOI) Marine Biomedical and Biotechnology Research Program (MBBR) scientists have been awarded a $345,716 grant by the National Institutes of Health (NIH) to identify marine natural products for their potential use in the treatment of pancreatic cancer.
A primary mission for the MBBR is to discover marine natural products that can be used as medicines or as tools to better understand the molecular basis of disease. MBBR has identified over 100 marine natural products with cancer fighting properties.
One current focus is to find potential treatments for pancreatic cancer, the fourth leading cause of cancer death in the United States. Pancreatic cancer has a 5-year survival rate of 6 percent, highlighting the need for new treatments.
Principal Investigator Dr. Esther Guzmán and co-investigator Dr. Amy Wright, director of the MBBR, plan to initiate a screening effort to discover inhibitors of the receptor for advanced glycation end products (RAGE) in pancreatic cancer cells using HBOI’s unique library of marine natural products. RAGE has emerged as an important regulator of inflammatory, stress and cell survival pathways, which contribute to the aggressiveness of pancreatic cancer.
MDPI has announced the publication of the following issue:
Mar. Drugs, Volume 11, Issue 3 (March 2013), Pages Pages 581-974
Table of Contents:
Editorial: Marine Drugs Best Paper Award 2013
Mar. Drugs 2013, 11(3), 581-583; doi:10.3390/md11030581
Marco Pelin, Sabrina Boscolo, Mark Poli, Silvio Sosa, Aurelia Tubaro and Chiara Florio
Article: Characterization of Palytoxin Binding to HaCaT Cells Using a Monoclonal Anti-Palytoxin Antibody
Mar. Drugs 2013, 11(3), 584-598; doi:10.3390/md11030584
Jean-Baptiste Gallé, Barthélémy Attioua, Marcel Kaiser, Anne-Marie Rusig, Annelise Lobstein and Catherine Vonthron-Sénécheau
Article: Eleganolone, a Diterpene from the French Marine Alga Bifurcaria bifurcata Inhibits Growth of the Human Pathogens Trypanosoma brucei and Plasmodium falciparum
Mar. Drugs 2013, 11(3), 599-610; doi:10.3390/md11030599
Soohyun Um, Yuna Pyee, Eun-Hee Kim, Sang Lee, Jongheon Shin and Dong-Chan Oh
Article: Thalassospiramide G, a New γ-Amino-Acid-Bearing Peptide from the Marine BacteriumThalassospira sp.
Mar. Drugs 2013, 11(3), 611-622; doi:10.3390/md11030611
Gerrit Gerwig, Henry Hocking, Reto Stöcklin, Johannis Kamerling and Rolf Boelens
Review: Glycosylation of Conotoxins
Mar. Drugs 2013, 11(3), 623-642; doi:10.3390/md11030623
Anna Carbone, Barbara Parrino, Paola Barraja, Virginia Spanò, Girolamo Cirrincione, Patrizia Diana, Armin Maier, Gerhard Kelter and Heinz-Herbert Fiebig
Article: Synthesis and Antiproliferative Activity of 2,5-bis(3′-Indolyl)pyrroles, Analogues of the Marine Alkaloid Nortopsentin
Mar. Drugs 2013, 11(3), 643-654; doi:10.3390/md11030643
Diego Orts, Steve Peigneur, Bruno Madio, Juliana Cassoli, Gabriela Montandon, Adriano Pimenta, José Bicudo, José Freitas, André Zaharenko and Jan Tytgat
Article: Biochemical and Electrophysiological Characterization of Two Sea Anemone Type 1 Potassium Toxins from a Geographically Distant Population of Bunodosoma caissarum
Mar. Drugs 2013, 11(3), 655-679; doi:10.3390/md11030655
Heidi Hannon and William Atchison
Review: Omega-Conotoxins as Experimental Tools and Therapeutics in Pain Management
Mar. Drugs 2013, 11(3), 680-699; doi:10.3390/md11030680
Zhi-Qiang Xiong, Jian-Feng Wang, Yu-You Hao and Yong Wang
Review: Recent Advances in the Discovery and Development of Marine Microbial Natural Products
Mar. Drugs 2013, 11(3), 700-717; doi:10.3390/md11030700
Xiaohong Wang, Heinz Schröder, Qingling Feng, Florian Draenert and Werner Müller
Review: The Deep-Sea Natural Products, Biogenic Polyphosphate (Bio-PolyP) and Biogenic Silica (Bio-Silica), as Biomimetic Scaffolds for Bone Tissue Engineering: Fabrication of a Morphogenetically-Active Polymer
Mar. Drugs 2013, 11(3), 718-746; doi:10.3390/md11030718
José Vázquez, Isabel Rodríguez-Amado, María Montemayor, Javier Fraguas, María González and Miguel Murado
Review: Chondroitin Sulfate, Hyaluronic Acid and Chitin/Chitosan Production Using Marine Waste Sources: Characteristics, Applications and Eco-Friendly Processes: A Review
Mar. Drugs 2013, 11(3), 747-774; doi:10.3390/md11030747
Zenglei Wang, Hua Tang, Pan Wang, Wei Gong, Mei Xue, Hongwei Zhang, Taofang Liu, Baoshu Liu, Yanghua Yi and Wen Zhang
Article: Bioactive Polyoxygenated Steroids from the South China Sea Soft Coral, Sarcophyton sp.
Mar. Drugs 2013, 11(3), 775-787; doi:10.3390/md11030775
Chi-Jen Tai, Jui-Hsin Su, Chiung-Yao Huang, Ming-Shyan Huang, Zhi-Hong Wen, Chang-Feng Dai and Jyh-Horng Sheu
Article: Cytotoxic and Anti-Inflammatory Eunicellin-Based Diterpenoids from the Soft Coral Cladiella krempfi
Mar. Drugs 2013, 11(3), 788-799; doi:10.3390/md11030788
Nils Jansen, Birgit Ohlendorf, Arlette Erhard, Torsten Bruhn, Gerhard Bringmann and Johannes Imhoff
Article: Helicusin E, Isochromophilone X and Isochromophilone XI: New Chloroazaphilones Produced by the Fungus Bartalinia robillardoides Strain LF550
Mar. Drugs 2013, 11(3), 800-816; doi:10.3390/md11030800
Ganjun Yuan, Kui Hong, Haipeng Lin, Zhigang She and Jia Li
Article: New Azalomycin F Analogs from Mangrove Streptomyces sp. 211726 with Activity against Microbes and Cancer Cells
Mar. Drugs 2013, 11(3), 817-829; doi:10.3390/md11030817
Victoria Suárez-Ulloa, Juan Fernández-Tajes, Vanessa Aguiar-Pulido, Ciro Rivera-Casas, Rodrigo González-Romero, Juan Ausio, Josefina Méndez, Julián Dorado and José Eirín-López
Article: The CHROMEVALOA Database: A Resource for the Evaluation of Okadaic Acid Contamination in the Marine Environment Based on the Chromatin-Associated Transcriptome of the Mussel Mytilus galloprovincialis
Mar. Drugs 2013, 11(3), 830-841; doi:10.3390/md11030830
Xiuli Xu, Liyuan Yin, Lijie Gao, Junhai Gao, Junhui Chen, Jingxi Li and Fuhang Song
Article: Two New Bromophenols with Radical Scavenging Activity from Marine Red AlgaSymphyocladia latiuscula
Mar. Drugs 2013, 11(3), 842-847; doi:10.3390/md11030842
M. Rashid, Somayeh Mahdavi and Serdar Kuyucak
Review: Computational Studies of Marine Toxins Targeting Ion Channels
Mar. Drugs 2013, 11(3), 848-869; doi:10.3390/md11030848
Chao-Yan Zhang, Ting Kong, Wen-Hui Wu and Min-Bo Lan
Article: The Protection of Polysaccharide from the Brown Seaweed Sargassum graminifoliumagainst Ethylene Glycol-Induced Mitochondrial Damage
Mar. Drugs 2013, 11(3), 870-880; doi:10.3390/md11030870
María Hortigüela and J. Wall
Article: Improved Detection of Domoic Acid Using Covalently Immobilised Antibody Fragments
Mar. Drugs 2013, 11(3), 881-895; doi:10.3390/md11030881
Yutaka Hata, Shikshya Timalsina and Sainawaer Maimaiti
Review: Okadaic Acid: A Tool to Study the Hippo Pathway
Mar. Drugs 2013, 11(3), 896-902; doi:10.3390/md11030896
Ying-Qing Wang and Ze-Hong Miao
Review: Marine-Derived Angiogenesis Inhibitors for Cancer Therapy
Mar. Drugs 2013, 11(3), 903-933; doi:10.3390/md11030903
Camila Lehnhardt Pires, Selma Rodrigues, Daniel Bristot, Henrique Gaeta, Daniela de Oliveira Toyama, Wladimir Lobo Farias and Marcos Toyama
Article: Evaluation of Macroalgae Sulfated Polysaccharides on the Leishmania (L.) amazonensisPromastigote
Mar. Drugs 2013, 11(3), 934-943; doi:10.3390/md11030934
Maria Serova, Armand de Gramont, Ivan Bieche, Maria Riveiro, Carlos Galmarini, Miguel Aracil, José Jimeno, Sandrine Faivre and Eric Raymond
Article: Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound
Mar. Drugs 2013, 11(3), 944-959; doi:10.3390/md11030944
Ling-Yan Dong, Jie Jin, Gao Lu and Xiao-Li Kang
Article: Astaxanthin Attenuates the Apoptosis of Retinal Ganglion Cells in db/db Mice by Inhibition of Oxidative Stress
Mar. Drugs 2013, 11(3), 960-974; doi:10.3390/md11030960
The northern German federal state Schleswig-Holstein is known as “land between the seas”. Already in 2004 its government launched the initiative “Sea Our Future” to pool and promote maritime issues. Schleswig-Holstein’s economy is closely linked to the North and the Baltic Sea. Marine Biotechnology as a future key technology is an integral part of it. Within the SUBMARINER project, Norgenta is responsible for the preparation of a regional development strategy for Marine Biotechnology in Schleswig-Holstein. The process included identification of the main industrial topics and markets (functional food, active pharmaceutical ingredients, and cosmetics) as well as academic topics (marine genomics, marine microbial diversity, biologically active substances, and biobanking). A SWOT analysis was carried out and series of activities were proposed.
Comparison of Tamoxifen with Edible Seaweed (Eucheuma cottonii L.) Extract in Suppressing Breast TumorPosted On: March 21, 2013
The extract of an edible red seaweed was found to be 27 percent more effective than standard chemo in shrinking breast tumors in rats while showing much less toxicity to liver and kidneys, and even improving the rats’ antioxidant status in both blood and tissues.
The tropical edible red seaweed (Eucheuma cottonii L.) is rich in nutrients and polyphenolic compounds that may suppress cancer through its antioxidant and antiproliferative properties. The study reports on rat mammary tumor suppression and tissue antioxidant status modulation by E. cottonii ethanol extract (ECE). The effect of orally administered ECE (100 mg/kg body-weight) was compared with that of tamoxifen (10 mg/kg body-weight). Rat was induced to develop mammary tumor with subcutaneous injection of LA-7 cells (6 × 10(6) cells/rat). The ECE was more effective than tamoxifen in suppressing tumor growth (27%), improving tissues (plasma, liver, and kidney) malondialdehyde concentrations, superoxide dismutase activity and erythrocyte glutathione concentrations (P < 0.05). Unlike tamoxifen, the ECE displayed little toxicity to the liver and kidneys.
The ECE exhibited strong anticancer effect with enzyme modulating properties, suggesting its potential as a suppressing agent for mammary gland tumor.
A new nasal spray from a marine microbe will help clear chronic sinusitis, which causes nasal congestion, difficulty in breathing, pain and swelling around your eyes and cheeks. A team of scientists and surgeons from Newcastle University are developing the spray with an enzyme isolated from a marine bug Bacillus licheniformis, found on the surface of seaweed.
Lab experiments showed that the enzyme, called NucB, dispersed 58 per cent of biofilms in chronic sinusitis formed by the marine bug. The biofilm acts as a slimy barrier to protect bugs from sprays or antibiotics, the journal Public Library of Science ONE reports.
10th International Marine Biotechnology Conference
Genome to phenome: understanding to sustainable use
Brisbane Convention and Exhibition Centre from 11-15 November 2013.
The International Marine Biotechnology Conference is the premier meeting in marine biotechnology and micro-biotechnologies. Dating back to 1989, previous IMBCs have been held in Japan (twice), The United States of America, Norway, Italy, Australia, Canada, Israel, China and Australia.
The 10th IMBC will showcase leading-edge developments in marine biotechnologies, from algal biotechnologies through to whole-organism biotechnologies and the application of marine genomics, metagenomics and chemistry in biomedicine, bioprocessing and aquaculture. Sustainable policies and practices will be at the fore throughout the conference.
Over the coming months further details about this meeting will come available, including a list of international plenary speakers and details on specific symposia. Along with this information, will be details on the registration, abstract submissions and trade displays.
The marine ecosystem is still an untapped reservoir of biologically active compounds, which have considerable potential to supply food ingredients towards development of new functional foods. With the goal of increasing the availability and chemical diversity of functional marine ingredients, much research has been developed using biotechnological tools to discover and produce new compounds.
This review summarizes the advances in biotechnological tools for production of functional ingredients, including enzymes, for the food industry. Tools involving biotechnological processes (bioreactors, fermentations, bioprocessing) and those involving genetic research designated as molecular biotechnology are discussed highlighting how they can be used in the controlled manipulation and utilization of marine organisms as sources of food ingredients, as well as discussing the most relevant shortcomings towards applications in new functional foods.
The conference program is complete however we like to invite delegates to present posters combined with short (5’) oral presentations.
Register to conference and send in your abstract within the 13th December 2012. For more info check: http://mabit.no/node/39
Presentation slots are available on all days during the conference.
Your poster and presentation should be relevant for one of the four sessions:
- Industrial applicability of marine proteins and low molecular compounds
- Bioprospecting related to aquaculture
- Marine lipids
- Bioactive compounds for health